Moreover, accumulating evidence demonstrates that the pharmacological inhibition of IRAP may hold promise as a valuable approach not only for the treatment of memory disorders and neurodegenerative diseases but also potentially for neuroprotection in connection with ischemic stroke and other cardiovascular disorders. The gene discussed is LNPEP; the disease is cardiovascular disorder.